Antisense therapy has generated waves of enthusiasm and disappointment. With a new drug about to be submitted for approval, is it on the cusp of becoming established as a platform technology?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Journal of Experimental & Clinical Cancer Research Open Access 13 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. The long march of antisense. Nat Rev Drug Discov 10, 401–402 (2011). https://doi.org/10.1038/nrd3474
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3474
This article is cited by
-
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Journal of Experimental & Clinical Cancer Research (2018)
-
Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
Molecular Therapy (2014)
-
In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide
Archives of Virology (2014)
-
Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration
Cell and Tissue Research (2012)